The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Summary: Inhibition of histone deacetylase (HDAC) is a promising mechanism for novel, anti‐myeloma agents. We investigated the effects of the novel HDAC inhibitor resminostat on multiple myeloma (MM) cells in vitro. Resminostat is a potent inhibitor of HDACs 1, 3 and 6 [50% inhibitory concentration (IC 50) = 43–72 nmol/l] representing HDAC classes I and II and induces hyperacetylation of histone H4 in MM cells. Low micromolar concentrations of resminostat abrogated cell growth and strongly induced apoptosis (IC 50 = 2·5–3 μmol/l in 3 out of 4 MM cell lines) in MM cell lines as well as primary MM cells. At 1 μmol/l, resminostat inhibited proliferation and induced G0/G1 cell cycle arrest in 3 out of 4 MM cell lines accompanied with decreased levels of cyclin D1, cdc25a, Cdk4 and pRb as well as upregulation of p21. Resminostat decreased phosphorylation of 4E‐BP1 and p70S6k indicating an interference with Akt pathway signalling. Treatment with resminostat resulted in increased protein levels of Bim and Bax and decreased levels of Bcl‐xL. Caspases 3, 8 and 9 were activated by resminostat. Furthermore, synergistic effects were observed for combinations of resminostat with melphalan and the proteasome inhibitors bortezomib and S‐2209. In conclusion, we have identified potent anti‐myeloma activity for this novel HDAC inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×
“In accordance with downregulation of cyclin D1, cdc25a and Cdk4, levels of p-Rb timedependently declined under resminostat treatment. p53 is a transcription factor crucial for G1 phase checkpoint control and is activated by DNA damage (Lane, 1992).”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 10×
“Epigenetic dysregulation is increasingly recognized as a crucial event in the formation and progression of cancer (Lund & van Lohuizen, 2004; Toyota & Issa, 2005; Baylin & Ohm, 2006; Bolden et al, 2006).”
BackgroundInfluentialHistone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884 · cited 1×
“Acetylation of lysine residues within histone tails by histone acetyl transferases (HATs) loosens chromatin structure thus rendering target genes more accessible for transcription factors (Grunstein, 1997; Roth et al, 2001).”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 2×
“HDAC inhibitors (HDACi) have emerged as novel drugs with potent anti-cancer activity both in preclinical experiments and clinical trials (Marks et al, 2001; Johnstone, 2002; Drummond et al, 2005; Bolden et al, 2006; Batty et al, 2009).”
BackgroundHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515 · cited 3×
“Miscellaneous mechanisms have been shown to be implicated in the anti-cancer action of HDACi, including activation of tumour necrosis factor (TNF) family receptors, activation of the intrinsic apoptotic pathway as well as generation of reactive oxygen species (Marks et al, 2001; Johnstone, 2002; Bolden et al, 2006; Mi…”
BackgroundAcetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754 · cited 12×
“Conversely, histone deacetylases (HDACs) catalyze histone deacetylation resulting in chromatin compaction and transcriptional repression (Ruthenburg et al, 2007; Haberland et al, 2009).”
BackgroundInfluentialSirtuins in aging and age-related disease
Longo, V. D., & Kennedy, B. K. (2006) · Cell · doi:10.1016/j.cell.2006.07.002 · Cited by 628 · cited 1×
“Sirtuins are sometimes referred to as class III HDACs but are commonly regarded as a distinct family of deacteylases (Guarente, 2006; Longo & Kennedy, 2006).”
BackgroundWilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · cited 2×
“Moreover, siRNA mediated knockdown of specific HDACs in tumour cells has been shown to inhibit cell growth and survival (Glaser et al, 2003; Zhu et al, 2004; Bolden et al, 2006; Wilson et al, 2006).”
BackgroundUnraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566 · cited 1×
“Class IIa HDACs are unique in that they exhibit only minimal intrinsic enzymatic activity (Lahm et al, 2007) yet retaining the ability to repress gene transcription, possibly by acting as an adaptor molecule for class I HDACs (Fischle et al, 2002).”
Background
Cited by
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Metadata
- Authors
- Mandl‐Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F., Schmidmaier, R., & Baumann, P.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2010-04-25
- Volume
- 149
- Issue
- 4
- Pages
- 518-528
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1497672106
- Cited by
- 81
- References
- 12
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. https://app.cochat.ai/papers/10.1111/j.1365-2141.2010.08124.x
- The paper
- Mandl‐Weber, S., Meinel, F. G., Jankowsky, R., Oduncu, F., Schmidmaier, R., & Baumann, P. (2010). The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2010.08124.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.